公开(公告)号：US20130017975A1

公开(公告)日：2013-01-17

申请号：US13636782

申请日：2011-03-22

申请人： Young Hwa Chung ,  Neung Hwa Park ,  Eun Sil Yu ,  Young-Joo Lee ,  Jeong A Kim ,  Dan-Bi Lee ,  Sae-Hwan Lee ,  Jong-Eun Lee

发明人： Young Hwa Chung ,  Neung Hwa Park ,  Eun Sil Yu ,  Young-Joo Lee ,  Jeong A Kim ,  Dan-Bi Lee ,  Sae-Hwan Lee ,  Jong-Eun Lee

IPC分类号： C40B30/04 ,  C40B40/06 ,  C12Q1/68 ,  C07H21/04

CPC分类号： C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/156

摘要： Single nucleotide polymorphisms (SNP) for predicting prognosis of hepatocellular carcinoma after curative surgical resection are provided. The SNPs have a significant correlation with an over-expression of MTA1 which is useful prognostic factor for prediction of prognosis or poor survival after curative surgical resection of hepatocellular carcinoma. Therefore, the SNPs can be used in developing micro-arrays or test kits for prediction of the prognosis of hepatocellular carcinoma, and in screening drugs to improve poor prognosis of hepatocellular carcinoma after curative surgical resection.

摘要翻译： 提供单核苷酸多态性（SNP），用于预测治疗性手术切除后肝细胞癌的预后。 单核苷酸多态性与MTA1的过表达具有显着相关性，MTA1对肝细胞癌治愈手术切除后预后的预后或生存率差是有用的预后因素。 因此，SNP可用于开发微阵列或测试试剂盒，用于预测肝细胞癌的预后，并可用于筛选药物以改善治愈性手术切除后肝细胞癌的预后不良。

公开(公告)号：US20110171661A1

公开(公告)日：2011-07-14

申请号：US13057029

申请日：2008-08-26

申请人： Young Hwa Chung ,  Eun Sil Yu ,  Soo Hyung Ryu ,  Kyu Won Kim ,  Jeong A Kim

发明人： Young Hwa Chung ,  Eun Sil Yu ,  Soo Hyung Ryu ,  Kyu Won Kim ,  Jeong A Kim

IPC分类号： G01N33/53

CPC分类号： G01N33/57438 ,  G01N2800/54

摘要： Provided are a method of diagnosing the recurrence or possibility of recurrence of hepatocellular carcinoma after hepatocellular carcinoma surgery and a method of screening a drug for preventing the recurrence of hepatocellular carcinoma after hepatocellular carcinoma surgery and treating hepatocellular carcinoma. Specifically, the recurrence or possibility of recurrence of hepatocellular carcinoma after hepatocellular carcinoma surgery is diagnosed and a drug for preventing the recurrence of hepatocellular carcinoma after surgery and treating hepatocellular carcinoma is screened, by measuring expression levels of a metastatic tumor antigen 1 or metastasis associated 1 (MTA1) protein in a biological sample taken from a patient in which hepatocellular carcinoma recurs or is likely to recur after hepatocellular carcinoma surgery and comparing the measured expression levels of the MTA1 protein with those of a normal control group.

摘要翻译： 提供一种诊断肝细胞癌手术后肝细胞癌复发或复发可能性的方法，以及筛选肝细胞癌手术治疗肝细胞癌后肝细胞癌复发的药物方法。 具体来说，通过测定转移性肿瘤抗原1或转移相关的表达水平，筛选肝细胞癌手术后肝细胞癌复发或复发的可能性，并筛选用于预防手术后肝细胞癌复发和治疗肝细胞癌的药物 （MTA1）蛋白质，其中肝细胞癌复发或可能在肝细胞癌手术后复发的患者中获取，并比较测量的MTA1蛋白表达水平与正常对照组的表达水平。